Lucentis vs PDT: which is more cost-effective?
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration, from the December 2008 issue of Clinical Therapeutics.
Please click here to read the abstract.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Recent Videos
Related Content
